Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 13/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4330460 | 1.00 | GRM2 (0.39) | GRM2HTR2ATSHRALDH1A1KDM4E | |
| SCHEMBL4330462 | 1.00 | GRM2 (0.39) | GRM2HTR2ATSHRALDH1A1KDM4E | |
| SCHEMBL4096799 | 0.82 | GRM2 (0.58) | GRM2HTR2AALDH1A1HTT | |
| SCHEMBL4332334 | 0.82 | GRM2 (0.58) | GRM2HTR2AALDH1A1HTT | |
| SCHEMBL4332336 | 0.82 | GRM2 (0.58) | GRM2HTR2AALDH1A1HTT | |
| SCHEMBL4325022 | 0.79 | P2RX7 (0.41) | GRM2HTR2AKDM4EP2RX7 | |
| SCHEMBL4333757 | 0.79 | P2RX7 (0.41) | GRM2HTR2AKDM4EP2RX7 | |
| SCHEMBL4325016 | 0.79 | P2RX7 (0.41) | GRM2HTR2AKDM4EP2RX7 | |
| SCHEMBL4330213 | 0.78 | GRM2 (0.48) | GRM2HTR2A | |
| SCHEMBL4337443 | 0.78 | GRM2 (0.48) | GRM2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618960-B2 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-17 | — | — | US | disclosed |
| EP-1953154-A1 | MORPHOLINE TYPE CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070117798-A1 | Morpholine type cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117798-A1 | Morpholine type cinnamide compound | MLX, XDH, NOX4 | GRM2 1761/4885HTR2A 2030/4885TSHR 1540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.